Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vilazodone in Generalized Anxiety Disorder
NCT01766401Phase 3Completed
- Sponsor
- Forest Laboratories
- Start
- Jan 2013
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in generalized anxiety disorder (GAD) comparing Vilazodone with Placebo (2 arms). Primary endpoint: Hamilton Rating Scale for Anxiety Total Score at 8 weeks. Started Jan 2013; status: completed.
02
Drugs
vilazodone
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT01766401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01766401.